Brokerages expect Endo International PLC (NASDAQ:ENDP) (TSE:ENL) to report earnings of $0.53 per share for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Endo International’s earnings. The lowest EPS estimate is $0.49 and the highest is $0.57. Endo International posted earnings of $0.71 per share in the same quarter last year, which would indicate a negative year over year growth rate of 25.4%. The firm is expected to issue its next quarterly earnings results on Thursday, November 14th.

On average, analysts expect that Endo International will report full year earnings of $2.17 per share for the current fiscal year, with EPS estimates ranging from $2.11 to $2.23. For the next year, analysts expect that the company will report earnings of $2.34 per share, with EPS estimates ranging from $1.71 to $3.13. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Endo International.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Monday, August 5th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. Endo International had a negative net margin of 19.98% and a negative return on equity of 129.30%. The firm had revenue of $699.71 million for the quarter, compared to analysts’ expectations of $694.60 million. During the same quarter in the previous year, the company earned $0.76 earnings per share. The company’s revenue for the quarter was down 2.1% compared to the same quarter last year.

Several research analysts have issued reports on ENDP shares. Morgan Stanley set a $2.00 target price on shares of Endo International and gave the stock a “sell” rating in a report on Friday, August 9th. Royal Bank of Canada restated a “hold” rating and issued a $6.00 price target on shares of Endo International in a report on Thursday, August 8th. Barclays began coverage on shares of Endo International in a research note on Tuesday, June 11th. They issued an “equal weight” rating and a $6.00 target price for the company. Cantor Fitzgerald lowered their target price on shares of Endo International from $18.00 to $4.75 and set a “neutral” rating for the company in a research note on Wednesday, June 12th. Finally, Citigroup cut shares of Endo International from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $19.00 to $5.00 in a research note on Monday, June 17th. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $7.89.

NASDAQ:ENDP traded down $0.04 during mid-day trading on Friday, hitting $3.92. 167,274 shares of the company’s stock were exchanged, compared to its average volume of 9,744,917. The company has a market cap of $929.40 million, a PE ratio of 1.36 and a beta of 1.23. Endo International has a one year low of $1.97 and a one year high of $18.50. The business has a fifty day moving average price of $2.77 and a 200 day moving average price of $5.64.

In other Endo International news, Director Roger H. Kimmel sold 34,951 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $3.93, for a total transaction of $137,357.43. Following the completion of the transaction, the director now directly owns 148,309 shares of the company’s stock, valued at approximately $582,854.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.50% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of ENDP. Oregon Public Employees Retirement Fund increased its holdings in shares of Endo International by 1.8% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 77,330 shares of the company’s stock valued at $621,000 after purchasing an additional 1,397 shares in the last quarter. Mason Street Advisors LLC increased its holdings in shares of Endo International by 3.4% during the 1st quarter. Mason Street Advisors LLC now owns 64,141 shares of the company’s stock valued at $515,000 after purchasing an additional 2,134 shares in the last quarter. Piedmont Investment Advisors Inc. increased its holdings in shares of Endo International by 5.8% during the 1st quarter. Piedmont Investment Advisors Inc. now owns 50,737 shares of the company’s stock valued at $407,000 after purchasing an additional 2,795 shares in the last quarter. Comerica Bank increased its holdings in shares of Endo International by 2.1% during the 1st quarter. Comerica Bank now owns 198,605 shares of the company’s stock valued at $1,650,000 after purchasing an additional 4,001 shares in the last quarter. Finally, Arizona State Retirement System increased its holdings in shares of Endo International by 1.4% during the 2nd quarter. Arizona State Retirement System now owns 312,262 shares of the company’s stock valued at $1,287,000 after purchasing an additional 4,167 shares in the last quarter. 95.80% of the stock is owned by institutional investors.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Featured Story: Momentum Investing

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.